# Clinical trial results:
# Persistence of antibodies after full vaccination course with GSK Biologicals' Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age

## Summary

| | |
|---|---|
| EudraCT number | 2008-007846-69 |
| Trial protocol | DE ES |
| Global end of trial date | 21 November 2012 |

**Results information**

| | |
|---|---|
| Result version number | v2 (current) |
| This version publication date | 05 August 2016 |
| First version publication date | 23 April 2015 |
| Version creation reason | • Correction of full data set<br>Data (typos) were corrected. |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | 112830 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00891176 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | GlaxoSmithKline Biologicals |
| Sponsor organisation address | Rue de l'Institut 89, Rixensart, Belgium, B-1330 |
| Public contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |
| Scientific contact | Clinical Trials Call Center, GlaxoSmithKline Biologicals, 44 2089904466, GSKClinicalSupportHD@gsk.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 19 June 2013 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 21 November 2012 |
| Global end of trial reached? | Yes |
| Global end of trial date | 21 November 2012 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

At approximately 3, 4 and 6 years of age, in subjects who previously received a full vaccination course with Hib-MenC conjugate vaccine co-administrated with DTPa-containing and pneumococcal conjugate vaccines or with MenC conjugate vaccines co-administered with DTPa/Hib containing and GSK Biologicals' 10Pn-PD-DiT conjugate vaccines, and who participated in the blood sampling subset of study 10PN-PD-DIT-017:
•To evaluate the antibody persistence with respect to the MenC component of the Hib-MenC conjugate vaccine in terms of percentage of subjects with rSBA-MenC titres >= 1:8

Protection of trial subjects:

All subjects were supervised closely for at least 30 minutes following vaccination with appropriate medical treatment readily available. Vaccines were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines. Subjects were followed-up from the time the subject consents to participate in the study until she/he is discharged.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 14 May 2009 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Efficacy |
| Long term follow-up duration | 72 Months |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Germany: 108 |
| Country: Number of subjects enrolled | Spain: 186 |
| Country: Number of subjects enrolled | Poland: 306 |
| Worldwide total number of subjects | 600 |
| EEA total number of subjects | 600 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|---|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 600 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

All subjects who received the full vaccination course corresponding to their group in the primary vaccination study 107005 and in the booster vaccination study 109507 and who were part of the blood sampling subset were asked to participate in this long-term follow up study comprising 3 time points. No vaccine was given.

### Pre-assignment period milestones

| | |
|---|---|
| Number of subjects started | 600 |
| Number of subjects completed | 581 |

### Pre-assignment subject non-completion reasons

| | |
|---|---|
| Reason: Number of subjects | No vaccination received: 19 |

### Period 1

| | |
|---|---|
| Period 1 title | Long term Persistence (Visit 1) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Synflorix-Meningitec 1 Group |

Arm description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age.
No vaccine was administered during this long-term follow up study.

| | |
|---|---|
| Investigational medicinal product name | Pneumoccoccal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| | |
|---|---|
| Investigational medicinal product name | Infanrix Penta |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

| | |
|---|---|
| Investigational medicinal product name | Infanrix IPV |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain) No vaccine was administered during this long-term follow up study

| | |
|---|---|
| **Arm title** | Synflorix-NeisVac-C 1 Group |

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age.
No vaccine was administered during this long-term follow up study

| | |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

| | |
|---|---|
| Investigational medicinal product name | Prevenar |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Arm title** | Synflorix-Menitorix 1 Group |
|---|---|

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| Investigational medicinal product name | Meningitec |
|---|---|
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study

| Investigational medicinal product name | Infanrix hexa |
|---|---|
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study

| **Arm title** | Prevenar-Menitorix 1 Group |
|---|---|

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Number of subjects in period 1[1]** | Synflorix-Meningitec 1 Group | Synflorix-NeisVac-C 1 Group | Synflorix-Menitorix 1 Group |
|---|---|---|---|
| Started | 144 | 147 | 149 |
| Completed | 144 | 147 | 149 |

| **Number of subjects in period 1[1]** | Prevenar-Menitorix 1 Group |
|---|---|
| Started | 141 |
| Completed | 141 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Some subjects were enrolled but did not start the trial.

## Period 2

| | |
|---|---|
| Period 2 title | Long term Persistence (Visit 2) |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Synflorix-Meningitec 2 Group |

Arm description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
(In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Arm title** | Synflorix-NeisVac-C 2 Group |
|---|---|

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
(In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Arm type | Active comparator |
|---|---|
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Arm title** | Synflorix-Menitorix 2 Group |
|---|---|

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Arm type | Experimental |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Arm title** | Prevenar-Menitorix 2 Group |
|---|---|

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Arm type | Experimental |
|---|---|

| | |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Number of subjects in period 2[2]** | Synflorix-Meningitec 2 Group | Synflorix-NeisVac-C 2 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|
| Started | 140 | 142 | 142 |
| Completed | 140 | 142 | 142 |

| **Number of subjects in period 2[2]** | Prevenar-Menitorix 2 Group |
|---|---|
| Started | 137 |
| Completed | 137 |

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: Some subjects did not come back for the subsequent visits.

## Period 3

| | |
|---|---|
| Period 3 title | Long term Persistence (Visit 3) |
| Is this the baseline period? | No |
| Allocation method | Non-randomised - controlled |
| Blinding used | Not blinded |

## Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Synflorix-Meningitec 3 Group |

Arm description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| | |
|---|---|
| **Arm title** | Synflorix-NeisVac-C 3 Group |

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
(In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Menitorix |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| | |
|---|---|
| **Arm title** | Synflorix-Menitorix 3 Group |

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| | |
|---|---|
| **Arm title** | Prevenar-Menitorix 3 Group |

Arm description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| | |
|---|---|
| Arm type | Experimental |

| | |
|---|---|
| Investigational medicinal product name | Pneumococcal conjugate vaccine GSK1024850A |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.

| **Number of subjects in period 3[3]** | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 3 Group |
|---|---|---|---|
| Started | 131 | 138 | 135 |
| Completed | 131 | 138 | 135 |

| **Number of subjects in period 3[3]** | Prevenar-Menitorix 3 Group |
|---|---|
| Started | 135 |
| Completed | 135 |

Notes:

[3] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: Some subjects did not come back for the subsequent visits.

## Baseline characteristics

### Reporting groups

| Reporting group title | Synflorix-Meningitec 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-NeisVac-C 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-Menitorix 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Prevenar-Menitorix 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group values | Synflorix-Meningitec 1 Group | Synflorix-NeisVac-C 1 Group | Synflorix-Menitorix 1 Group |
|---|---|---|---|
| Number of subjects | 144 | 147 | 149 |
| Age categorical<br>Units: Subjects | | | |
| In utero | | | |
| Preterm newborn infants (gestational age < 37 wks) | | | |
| Newborns (0-27 days) | | | |
| Infants and toddlers (28 days-23 months) | | | |
| Children (2-11 years) | | | |
| Adolescents (12-17 years) | | | |

| | | | |
|---|---|---|---|
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 37.1 | 37.2 | 37.3 |
| standard deviation | ± 1.17 | ± 1.2 | ± 1.18 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 71 | 65 | 86 |
| Male | 73 | 82 | 63 |

| **Reporting group values** | Prevenar-Menitorix 1 Group | Total | |
|---|---|---|---|
| Number of subjects | 141 | 581 | |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | | 0 | |
| Newborns (0-27 days) | | 0 | |
| Infants and toddlers (28 days-23 months) | | 0 | |
| Children (2-11 years) | | 0 | |
| Adolescents (12-17 years) | | 0 | |
| Adults (18-64 years) | | 0 | |
| From 65-84 years | | 0 | |
| 85 years and over | | 0 | |
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 37.3 | | |
| standard deviation | ± 1.28 | - | |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 71 | 293 | |
| Male | 70 | 288 | |

## End points

### End points reporting groups

| Reporting group title | Synflorix-Meningitec 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-NeisVac-C 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-Menitorix 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Prevenar-Menitorix 1 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Synflorix-Meningitec 2 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-NeisVac-C 2 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.

3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-Menitorix 2 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Prevenar-Menitorix 2 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Synflorix-Meningitec 3 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study 107005:
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-NeisVac-C 3 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age.
3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland, subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations).
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| Reporting group title | Synflorix-Menitorix 3 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.
During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

| Reporting group title | Prevenar-Menitorix 3 Group |
|---|---|

Reporting group description:

Subjects who received concomitantly in the primary study (107005):
3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age.
3 primary doses of Pediarix intramuscularly into the upper left thigh at 2, 4 and 6 months of age.

During the booster study (109507), subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Pediarix

## Primary: Number of subjects with Meningoccoccal serogroup C serum bactericidal titers using rabitt complement (rSBA-MenC) equal to or above the cut-off value 1:8

| End point title | Number of subjects with Meningoccoccal serogroup C serum bactericidal titers using rabitt complement (rSBA-MenC) equal to or above the cut-off value 1:8[1] |
|---|---|

End point description:

| End point type | Primary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The scope of this primary endpoint was descriptive, no statistical analyses were conducted.

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 139 | 134 | 128 | 146 |
| Units: Subjects | | | | |
| rSBA-MenC | 120 | 97 | 31 | 144 |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 137 | 137 | 143 | 128 |
| Units: Subjects | | | | |
| rSBA-MenC | 132 | 55 | 127 | 108 |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 137 | 128 | 134 |
| Units: Subjects | | | | |
| rSBA-MenC | 50 | 113 | 98 | 34 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-polyribosyl -ribitol phosphate (Anti-PRP) and antibody concentration equal to or above cut-off

| End point title | Number of subjects with anti-polyribosyl -ribitol phosphate (Anti-PRP) and antibody concentration equal to or above cut-off |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age. The cut-off were 0.15 ug/mL and 1.0 ug/mL

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 132 | 134 | 127 | 139 |
| Units: Subjects | | | | |
| ≥ 0.15 µg/mL | 132 | 133 | 126 | 139 |
| ≥ 1.0 µg/mL | 101 | 88 | 85 | 105 |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 136 | 134 | 137 | 130 |
| Units: Subjects | | | | |
| ≥ 0.15 µg/mL | 134 | 132 | 137 | 130 |
| ≥ 1.0 µg/mL | 85 | 77 | 127 | 117 |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 138 | 133 | 132 |
| Units: Subjects | | | | |
| ≥ 0.15 µg/mL | 130 | 138 | 132 | 132 |
| ≥ 1.0 µg/mL | 110 | 115 | 106 | 100 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with pneumoccoccal serotypes concentration equal to and above the cut-off values

| End point title | Number of subjects with pneumoccoccal serotypes concentration equal to and above the cut-off values |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 141 | 136 | 128 | 146 |
| Units: Subjects | | | | |
| Anti-1 | 138 | 130 | 121 | 143 |
| Anti-4 | 138 | 130 | 108 | 141 |
| Anti-5 | 140 | 136 | 125 | 144 |
| Anti-6B | 137 | 131 | 125 | 143 |
| Anti-7F | 141 | 135 | 125 | 146 |
| Anti-9V | 138 | 135 | 125 | 144 |
| Anti14 | 141 | 136 | 128 | 146 |
| Anti-18 C | 141 | 136 | 127 | 146 |
| Anti-19F | 141 | 135 | 128 | 146 |
| Anti-23 | 140 | 133 | 127 | 145 |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 138 | 137 | 144 | 133 |
| Units: Subjects | | | | |
| Anti-1 | 135 | 129 | 135 | 124 |
| Anti-4 | 133 | 123 | 140 | 127 |
| Anti-5 | 137 | 131 | 142 | 131 |
| Anti-6B | 134 | 133 | 139 | 125 |
| Anti-7F | 138 | 134 | 141 | 130 |
| Anti-9V | 135 | 133 | 141 | 128 |
| Anti14 | 138 | 137 | 144 | 132 |
| Anti-18 C | 138 | 136 | 140 | 130 |
| Anti-19F | 136 | 137 | 144 | 133 |
| Anti-23 | 137 | 136 | 140 | 126 |

| End point values | Synflorix- | Prevenar- | Prevenar- | Prevenar- |
|---|---|---|---|---|

| | Menitorix 3 Group | Menitorix 1 Group | Menitorix 2 Group | Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 140 | 136 | 133 |
| Units: Subjects | | | | |
| Anti-1 | 114 | 83 | 100 | 101 |
| Anti-4 | 106 | 133 | 132 | 126 |
| Anti-5 | 124 | 101 | 115 | 112 |
| Anti-6B | 128 | 137 | 132 | 130 |
| Anti-7F | 129 | 68 | 85 | 113 |
| Anti-9V | 126 | 139 | 135 | 131 |
| Anti14 | 130 | 140 | 136 | 133 |
| Anti-18 C | 125 | 139 | 136 | 128 |
| Anti-19F | 130 | 137 | 136 | 133 |
| Anti-23 | 128 | 139 | 134 | 133 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with opsonophagocytic activity

| End point title | Number of subjects with opsonophagocytic activity |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-NeisVac-C 1 Group | Synflorix-Menitorix 1 Group | Prevenar-Menitorix 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 131 | 131 | 131 | 132 |
| Units: Subjects | | | | |
| Opsono-1 [N=131;131;131;131] | 30 | 32 | 29 | 14 |
| Opsono-4 [N=126;127;129;128] | 54 | 48 | 43 | 77 |
| Opsono-5 [N=130;130;129;132] | 73 | 47 | 55 | 5 |
| Opsono-6B [N=128;127;124;131] | 84 | 81 | 78 | 115 |
| Opsono-7F [N=131;130;131;130] | 128 | 130 | 131 | 126 |
| Opsono-9V [N=131;131;129;132] | 127 | 131 | 127 | 124 |
| Opsono-14 [N=129;128;128;131] | 110 | 118 | 106 | 112 |
| Opsono-18C [N=126;121;123;122] | 51 | 68 | 44 | 48 |
| Opsono-19F [N=130;130;131;132] | 105 | 108 | 89 | 91 |
| Opsono-23F [N=125;124;125;132] | 106 | 112 | 113 | 129 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Antibody concentrations against vaccine pneumococcal serotypes

| End point title | Antibody concentrations against vaccine pneumococcal serotypes |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 141 | 136 | 128 | 146 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-1 | 0.26 (0.22 to 0.3) | 0.22 (0.19 to 0.27) | 0.19 (0.16 to 0.23) | 0.23 (0.19 to 0.26) |
| Anti-4 | 0.27 (0.23 to 0.32) | 0.22 (0.19 to 0.26) | 0.14 (0.11 to 0.17) | 0.23 (0.2 to 0.27) |
| Anti-5 | 0.46 (0.39 to 0.54) | 0.47 (0.37 to 0.59) | 0.37 (0.3 to 0.45) | 0.39 (0.33 to 0.46) |
| Anti-6B | 0.59 (0.45 to 0.76) | 0.74 (0.53 to 1.01) | 1.71 (1.32 to 2.23) | 0.56 (0.45 to 0.71) |
| Anti-7F | 0.58 (0.5 to 0.67) | 0.51 (0.41 to 0.63) | 0.61 (0.49 to 0.78) | 0.51 (0.43 to 0.59) |
| Anti-9V | 0.6 (0.49 to 0.73) | 0.52 (0.42 to 0.65) | 0.76 (0.56 to 1.01) | 0.54 (0.44 to 0.66) |
| Anti-14 | 1.33 (1.04 to 1.7) | 1.51 (1.18 to 1.92) | 2.84 (2.17 to 3.73) | 1.09 (0.88 to 1.35) |
| Anti-18C | 0.6 (0.5 to 0.71) | 0.49 (0.41 to 0.59) | 0.52 (0.41 to 0.66) | 0.84 (0.73 to 0.97) |
| Anti-19F | 2.06 (1.58 to 2.69) | 2.66 (1.92 to 3.67) | 3.91 (3.01 to 5.1) | 1.63 (1.27 to 2.09) |
| Anti-23F | 0.73 (0.58 to 0.92) | 0.98 (0.71 to 1.35) | 1.71 (1.26 to 2.3) | 0.69 (0.55 to 0.88) |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 138 | 137 | 144 | 133 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-1 | 0.21 (0.17 to 0.26) | 0.22 (0.17 to 0.27) | 0.21 (0.18 to 0.25) | 0.18 (0.15 to 0.21) |

| | | | | |
|---|---|---|---|---|
| Anti-4 | 0.21 (0.18 to 0.25) | 0.14 (0.11 to 0.17) | 0.23 (0.2 to 0.27) | 0.2 (0.17 to 0.24) |
| Anti-5 | 0.36 (0.3 to 0.42) | 0.31 (0.26 to 0.37) | 0.41 (0.35 to 0.5) | 0.34 (0.28 to 0.42) |
| Anti-6B | 0.65 (0.49 to 0.86) | 1.13 (0.87 to 1.48) | 0.63 (0.47 to 0.84) | 0.78 (0.57 to 1.06) |
| Anti-7F | 0.44 (0.37 to 0.52) | 0.59 (0.46 to 0.74) | 0.54 (0.45 to 0.66) | 0.46 (0.37 to 0.58) |
| Anti-9V | 0.61 (0.46 to 0.81) | 0.67 (0.51 to 0.88) | 0.47 (0.39 to 0.57) | 0.54 (0.4 to 0.72) |
| Anti-14 | 1.57 (1.25 to 1.97) | 2.22 (1.72 to 2.86) | 1 (0.8 to 1.25) | 1.41 (1.1 to 1.82) |
| Anti-18C | 0.81 (0.67 to 0.98) | 0.75 (0.6 to 0.94) | 0.59 (0.48 to 0.71) | 0.6 (0.48 to 0.75) |
| Anti-19F | 2.36 (1.7 to 3.29) | 3.94 (2.99 to 5.2) | 1.35 (1.05 to 1.72) | 2.5 (1.8 to 3.48) |
| Anti-23F | 0.84 (0.65 to 1.1) | 1.7 (1.27 to 2.26) | 0.62 (0.46 to 0.82) | 0.98 (0.69 to 1.39) |

| **End point values** | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 131 | 140 | 136 | 134 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-1 | 0.2 (0.15 to 0.26) | 0.07 (0.06 to 0.09) | 0.08 (0.07 to 0.1) | 0.11 (0.09 to 0.13) |
| Anti-4 | 0.12 (0.1 to 0.15) | 0.35 (0.29 to 0.42) | 0.32 (0.27 to 0.39) | 0.24 (0.19 to 0.29) |
| Anti-5 | 0.3 (0.25 to 0.37) | 0.09 (0.07 to 0.1) | 0.1 (0.08 to 0.11) | 0.13 (0.11 to 0.15) |
| Anti-6B | 1.28 (1 to 1.64) | 0.95 (0.77 to 1.18) | 0.99 (0.76 to 1.29) | 1.73 (1.38 to 2.16) |
| Anti-7F | 0.64 (0.5 to 0.82) | 0.07 (0.05 to 0.09) | 0.09 (0.07 to 0.12) | 0.24 (0.18 to 0.32) |
| Anti-9V | 0.57 (0.42 to 0.79) | 0.7 (0.57 to 0.85) | 0.72 (0.57 to 0.91) | 0.65 (0.51 to 0.83) |
| Anti-14 | 2.81 (2.07 to 3.81) | 1.48 (1.23 to 1.78) | 1.71 (1.38 to 2.12) | 2.59 (2.08 to 3.23) |
| Anti-18C | 0.56 (0.43 to 0.74) | 0.59 (0.5 to 0.7) | 0.49 (0.4 to 0.59) | 0.49 (0.39 to 0.62) |
| Anti-19F | 4.24 (3.3 to 5.45) | 1.48 (1.07 to 2.05) | 2.41 (1.78 to 3.25) | 3.11 (2.48 to 3.91) |
| Anti-23F | 1.41 (1.06 to 1.87) | 1.36 (1.07 to 1.73) | 1.56 (1.16 to 2.09) | 2.99 (2.32 to 3.86) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-protein D (anti-PD) antibody concentrations equal or above cut off values

| End point title | Number of subjects with anti-protein D (anti-PD) antibody concentrations equal or above cut off values |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| **End point values** | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 140 | 136 | 128 | 145 |
| Units: Subjects | | | | |
| Anti-PD | 132 | 127 | 113 | 137 |

| **End point values** | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 138 | 137 | 144 | 129 |
| Units: Subjects | | | | |
| Anti-PD | 128 | 119 | 136 | 115 |

| **End point values** | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 131 | 139 | 132 | 133 |
| Units: Subjects | | | | |
| Anti-PD | 113 | 69 | 75 | 74 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Concentration of antibodies against protein D

| End point title | Concentration of antibodies against protein D |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 140 | 136 | 128 | 145 |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD | 494.6 (414 to 591) | 401.1 (338.3 to 475.6) | 284.7 (239.5 to 338.4) | 444.8 (373.2 to 530.1) |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 138 | 137 | 144 | 129 |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD | 387.2 (326.7 to 458.9) | 278 (236.3 to 327.1) | 439.8 (366.4 to 527.9) | 334.8 (277.7 to 403.7) |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 131 | 139 | 132 | 133 |
| Units: EL.U/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PD | 266.1 (222.2 to 318.8) | 100.3 (87.6 to 114.9) | 107.9 (94.6 to 123.1) | 105.2 (92.4 to 119.8) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values

| | |
|---|---|
| End point title | Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values |

End point description:

| | |
|---|---|
| End point type | Secondary |

End point timeframe:
At 3 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-NeisVac-C 1 Group | Synflorix-Menitorix 1 Group | Prevenar-Menitorix 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 107 | 102 | 105 | 102 |
| Units: Subjects | | | | |
| ≥ 10 mIU/mL | 105 | 96 | 102 | 99 |
| ≥ 100 mIU/mL | 77 | 81 | 74 | 74 |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

| End point title | Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:
At 3 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-NeisVac-C 1 Group | Synflorix-Menitorix 1 Group | Prevenar-Menitorix 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 107 | 102 | 105 | 102 |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HBs antibody concentrations | 367.5 (256.8 to 525.9) | 325.7 (228.3 to 464.7) | 288.1 (198.7 to 417.9) | 371.4 (254.1 to 542.8) |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with Meningoccoccal serogroup C serum bactericidal titers using rabitt complement (rSBA-MenC) equal to or above cut-off value 1:128

| End point title | Number of subjects with Meningoccoccal serogroup C serum bactericidal titers using rabitt complement (rSBA-MenC) equal |
|---|---|

| | |
|---|---|
| | to or above cut-off value 1:128 |

End point description:

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

At 3, 4 and 6 years of age

| **End point values** | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 139 | 134 | 128 | 146 |
| Units: Subjects | | | | |
| rSBA-MenC | 69 | 49 | 11 | 109 |

| **End point values** | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 137 | 137 | 143 | 128 |
| Units: Subjects | | | | |
| rSBA-MenC | 79 | 19 | 98 | 75 |

| **End point values** | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 137 | 128 | 134 |
| Units: Subjects | | | | |
| rSBA-MenC | 15 | 68 | 58 | 14 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Meningoccoccal serogroup C serum bactericidal (rSBA-MenC) titers

| | |
|---|---|
| End point title | Meningoccoccal serogroup C serum bactericidal (rSBA-MenC) titers |

End point description:

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 139 | 134 | 128 | 146 |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| rSBA-MenC titers | 100.5 (75.6 to 133.8) | 45.3 (33.2 to 61.8) | 7.2 (5.8 to 8.9) | 235.3 (189.1 to 292.7) |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 137 | 137 | 143 | 128 |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| rSBA-MenC titers | 146.8 (116.2 to 185.4) | 11.9 (8.9 to 16) | 167.5 (126 to 222.7) | 112.4 (81.8 to 154.6) |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 137 | 128 | 134 |
| Units: Titer | | | | |
| geometric mean (confidence interval 95%) | | | | |
| rSBA-MenC titers | 10.1 (7.9 to 12.9) | 84 (61.6 to 114.6) | 68.1 (48.4 to 95.9) | 8.5 (6.6 to 11.1) |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-polyribosyl -ribitol phosphate (anti-PRP) concentrations

| End point title | Anti-polyribosyl -ribitol phosphate (anti-PRP) concentrations |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 132 | 134 | 127 | 139 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PRP concentrations | 2.293 (1.87 to 2.812) | 1.767 (1.454 to 2.146) | 1.655 (1.339 to 2.045) | 2.222 (1.794 to 2.752) |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 136 | 134 | 137 | 130 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PRP concentrations | 1.738 (1.386 to 2.178) | 1.647 (1.298 to 2.09) | 4.177 (3.427 to 5.092) | 3.804 (3.092 to 4.679) |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 130 | 138 | 133 | 132 |
| Units: µg/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-PRP concentrations | 2.947 (2.396 to 3.624) | 3.636 (2.957 to 4.471) | 2.805 (2.297 to 3.425) | 2.558 (2.065 to 3.168) |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of subjects with Serious Adverse Events (SAEs)

| End point title | Number of subjects with Serious Adverse Events (SAEs) |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 3, 4 and 6 years of age

| End point values | Synflorix-Meningitec 1 Group | Synflorix-Meningitec 2 Group | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 1 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 144 | 140 | 131 | 147 |
| Units: Subjects | | | | |
| SAE(s) | 0 | 0 | 0 | 0 |
| Related SAE(s) | 0 | 0 | 0 | 0 |

| End point values | Synflorix-NeisVac-C 2 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 1 Group | Synflorix-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 142 | 138 | 149 | 142 |
| Units: Subjects | | | | |
| SAE(s) | 0 | 0 | 0 | 0 |
| Related SAE(s) | 0 | 0 | 0 | 0 |

| End point values | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 1 Group | Prevenar-Menitorix 2 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 135 | 141 | 137 | 135 |
| Units: Subjects | | | | |
| SAE(s) | 0 | 0 | 0 | 0 |
| Related SAE(s) | 0 | 0 | 0 | 0 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

| End point title | Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 4 years of age

| End point values | Synflorix-Meningitec 2 Group | Synflorix-NeisVac-C 2 Group | Synflorix-Menitorix 2 Group | Prevenar-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 95 | 102 | 98 | 98 |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HBs antibody concentrations | 273.5 (183.2 to 408.3) | 238.8 (165.6 to 344.3) | 174.6 (114.5 to 266.4) | 284.7 (190.7 to 425.1) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values

| End point title | Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values |
|---|---|

End point description:

Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.

| End point type | Secondary |
|---|---|

End point timeframe:

At 4 years of age

| End point values | Synflorix-Meningitec 2 Group | Synflorix-NeisVac-C 2 Group | Synflorix-Menitorix 2 Group | Prevenar-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 95 | 102 | 98 | 98 |
| Units: Subjects | | | | |
| ≥ 10 mIU/mL | 86 | 93 | 86 | 90 |
| ≥ 100 mIU/mL | 67 | 72 | 62 | 72 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with opsonophagocytic activity

| End point title | Number of subjects with opsonophagocytic activity |
|---|---|

End point description:

Opsonophagocytic activity was measured by a killing-assay. The results were presented as the dilution

of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer of 8.

| End point type | Secondary |
|---|---|

End point timeframe:

At 4 years of age

| **End point values** | Synflorix-Meningitec 2 Group | Synflorix-NeisVac-C 2 Group | Synflorix-Menitorix 2 Group | Prevenar-Menitorix 2 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 131 | 134 | 123 | 128 |
| Units: Subjects | | | | |
| Opsono-1 (n=131;134;123;128) | 33 | 32 | 20 | 12 |
| Opsono-4 (N=127;132;118;126) | 49 | 50 | 36 | 72 |
| Opsono-5 (N=129;132;122;128) | 65 | 46 | 40 | 5 |
| Opsono-6B (N=128;129;122;126) | 93 | 97 | 101 | 111 |
| Opsono-7F (N=131;134;123;128) | 131 | 134 | 123 | 126 |
| Opsono-9V (N=130;132;120;126) | 125 | 130 | 118 | 122 |
| Opsono-14 (N=126;128;114;121) | 96 | 105 | 95 | 110 |
| Opsono-18C (N=113;118;113;118) | 34 | 56 | 46 | 45 |
| Opsono-19F (N=131;133;123;128) | 87 | 88 | 80 | 89 |
| Opsono-23F (N=129133;119;121) | 98 | 108 | 86 | 111 |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations

| End point title | Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 6 years of age

| **End point values** | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 122 | 129 | 125 | 128 |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HBs antibody concentrations | 66.7 (47.2 to 94.1) | 64.7 (46.4 to 90.2) | 45.7 (32.2 to 64.8) | 85.4 (60.4 to 120.6) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-hepatitis B surface antigen (anti- HBs) antibody concentrations equal to or above cut-off values

| End point title | Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody concentrations equal to or above cut-off values |
|---|---|

End point description:

Cut-off values assessed were defined as equal to or above 10 milli-international units per milliliter (mIU/mL) or equal to or above 100 mIU/mL.

| End point type | Secondary |
|---|---|

End point timeframe:

At 6 years of age

| End point values | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 122 | 129 | 125 | 128 |
| Units: Subjects | | | | |
| ≥ 10 mIU/mL | 100 | 103 | 91 | 108 |
| ≥ 100 mIU/mL | 57 | 62 | 45 | 66 |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations as measured by ChemiLuminescence ImmunoAssay (CLIA)

| End point title | Anti-hepatitis B surface antigen (anti-HBs) antibody concentrations as measured by ChemiLuminescence ImmunoAssay (CLIA) |
|---|---|

End point description:

| End point type | Secondary |
|---|---|

End point timeframe:

At 6 years of age

| End point values | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 122 | 129 | 125 | 128 |
| Units: mIU/mL | | | | |
| geometric mean (confidence interval 95%) | | | | |
| Anti-HBs antibody concentrations | 66.7 (47.2 to 94.1) | 64.7 (46.4 to 90.2) | 45.7 (32.2 to 64.8) | 85.4 (60.4 to 120.6) |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody as measured by CLIA concentrations equal to or above cut-off values

| End point title | Number of subjects with anti-hepatitis B surface antigen (anti-HBs) antibody as measured by CLIA concentrations equal to or above cut-off values |
|---|---|

End point description:

Cut-off values assessed were defined as equal to or above 6.2 milli-international units per milliliter (mIU/mL) or equal to or above 10 mIU/mL or equal to or above 100 mIU/mL.

| End point type | Secondary |
|---|---|

End point timeframe:

At 6 years of age

| End point values | Synflorix-Meningitec 3 Group | Synflorix-NeisVac-C 3 Group | Synflorix-Menitorix 3 Group | Prevenar-Menitorix 3 Group |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 122 | 129 | 125 | 128 |
| Units: Subjects | | | | |
| ≥ 6.2 mIU/mL | 102 | 108 | 98 | 112 |
| ≥ 10 mIU/mL | 100 | 103 | 91 | 108 |
| ≥ 100 mIU/mL | 57 | 62 | 45 | 66 |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information[1]

Timeframe for reporting adverse events:

From last study contact of the booster study at 17-24 months of age (NCT00463437) until 6 years of age

Adverse event reporting additional description:

Since no vaccine was administered during the study, other adverse events were not assessed.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 16.0 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Synflorix-Meningitec Group |

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Reporting group title | Synflorix-NeisVac-C Group |

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.

| | |
|---|---|
| Reporting group title | Synflorix-Menitorix Group |

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.

| | |
|---|---|
| Reporting group title | Prevenar-Menitorix Group |

Reporting group description:

Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.

| Serious adverse events | Synflorix-Meningitec Group | Synflorix-NeisVac-C Group | Synflorix-Menitorix Group |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 144 (0.00%) | 0 / 147 (0.00%) | 0 / 149 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |

| **Serious adverse events** | Prevenar-Menitorix Group | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 141 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Synflorix-Meningitec Group | Synflorix-NeisVac-C Group | Synflorix-Menitorix Group |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 144 (0.00%) | 0 / 147 (0.00%) | 0 / 149 (0.00%) |

| **Non-serious adverse events** | Prevenar-Menitorix Group | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 0 / 141 (0.00%) | | |

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No non-serious adverse events were recorded in this study.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported